<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rates of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in those with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> newly started on insulin are less than in Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> but rise with time </plain></SENT>
<SENT sid="1" pm="."><plain>As insulin secretion declines, the ability to release glucagon is diminished </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="47" ids="28918,33568">Adrenaline</z:chebi> release partially compensates for deficient glucagon secretion but is vulnerable to repeated <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> leading to diminished sympathoadrenal activation </plain></SENT>
<SENT sid="3" pm="."><plain>Thus the inevitable decline in endogenous insulin, eventually produces a similar failure of physiological protection to <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> as in Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>